{
    "clinical_study": {
        "@rank": "30318", 
        "brief_summary": {
            "textblock": "To allow, on a compassionate use basis, zalcitabine (ddC) for pediatric patients with\n      symptomatic HIV disease who have failed treatment or who are intolerant to zidovudine (AZT),\n      or who have completed other ddC protocols, or who are ineligible for ongoing clinical\n      trials."
        }, 
        "brief_title": "An Open-Label Safety Program for the Use of Zalcitabine (Dideoxycytidine; ddC) in Pediatric Patients With Symptomatic HIV Infection Who Have Failed or Are Intolerant to AZT Monotherapy, or Who Have Completed Other ddC Protocols, or Are Ineligible for Other Ongoing Clinical Studies", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients receive ddC and are evaluated at study entry and every 3 months thereafter, until 3\n      months after ddC becomes approved for pediatric patients or the sponsor deems it necessary\n      to terminate the protocol."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  Symptomatic HIV infection.\n\n          -  Failure on or intolerance to AZT monotherapy OR completed other ddC protocols OR been\n             ineligible for other ongoing clinical trials.\n\n          -  Consent of parent or guardian required.\n\n        Note:\n\n          -  Patients who do not meet the eligibility requirements may discuss their cases with\n             the medical monitor."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "11 Years", 
            "minimum_age": "3 Months"
        }, 
        "enrollment": "600", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002118", 
            "org_study_id": "031F", 
            "secondary_id": "NV14610"
        }, 
        "intervention": {
            "intervention_name": "Zalcitabine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Zalcitabine"
        }, 
        "keyword": [
            "Zalcitabine", 
            "Acquired Immunodeficiency Syndrome", 
            "AIDS-Related Complex"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Nutley", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "07110"
                }, 
                "name": "Hoffmann - La Roche Inc"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "An Open-Label Safety Program for the Use of Zalcitabine (Dideoxycytidine; ddC) in Pediatric Patients With Symptomatic HIV Infection Who Have Failed or Are Intolerant to AZT Monotherapy, or Who Have Completed Other ddC Protocols, or Are Ineligible for Other Ongoing Clinical Studies", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "reference": {
            "PMID": "9179531", 
            "citation": "Adkins JC, Peters DH, Faulds D. Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection. Drugs. 1997 Jun;53(6):1054-80. Review."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002118"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 1997"
    }, 
    "geocoordinates": {
        "Hoffmann - La Roche Inc": "40.822 -74.16"
    }
}